文献速递瓣膜外科

年轻患者Ross手术与机械主动脉瓣置换的决策分析

The Ross procedure versus mechanical aortic valve replacement in young patients: a decision analysis.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

该研究构建概率马尔可夫微观模拟模型,比较年轻主动脉瓣疾病患者接受Ross手术与机械主动脉瓣置换(mAVR)的预期寿命和质量调整生命年。模型参数来自208对倾向评分匹配患者的单中心研究。结果显示,当Ross手术围术期死亡率低于2.5%时预期寿命优于mAVR,2.5%至5%时两者相当。

要点

  • Ross手术围术期死亡率<2.5%时,预期寿命优于mAVR。
  • 围术期死亡率2.5%–5%时,Ross手术与mAVR预期寿命相当。
  • 围术期死亡率4%–5.5%时,两者质量调整生命年相近。

核心结论

  • 当Ross手术围术期死亡率低于2.5%时,年轻主动脉瓣疾病患者的预期寿命可优于机械主动脉瓣置换。

研究设计与样本

  • 早期死亡和晚期并发症(死亡、卒中、出血、再手术)参数来自208例倾向评分匹配患者的单中心研究。

主要发现

  • Ross手术围术期死亡率以0.5%递增变化时,低于2.5%则预期寿命改善,2.5%至5%则与mAVR相当。
  • Ross手术围术期死亡率在4%至5.5%时,其获得的质量调整生命年与mAVR相似。
  • 当20年Ross再手术发生率为18%时,再手术死亡率低于7%则预期寿命改善。

关键数值与推荐

  • Ross手术围术期死亡率<2.5%:预期寿命优于mAVR。
  • Ross手术围术期死亡率2.5%–5%:预期寿命与mAVR相当。
  • Ross手术围术期死亡率4%–5.5%:质量调整生命年与mAVR相似。
  • 20年Ross再手术发生率18%时,再手术死亡率<7%则预期寿命改善。

临床怎么用

  • 对于年轻主动脉瓣疾病患者,选择Ross手术前应评估本中心围术期死亡率是否能控制在2.5%以下,以获取预期寿命获益。

局限性

  • 模型参数来自单中心208例倾向评分匹配患者的研究,外推性可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our goal was to determine the range of perioperative mortality rates associated with the Ross procedure that results in a life expectancy similar to that seen with mechanical aortic valve replacement (mAVR) in young patients with aortic valve disease. METHODS: A fully probabilistic Markov microsimulation model with 1000 outer loops and 10 000 inner loops was constructed to compare gain in life expectancy and quality-adjusted life years between the index treatment with the Ross procedure versus mAVR for a theoretical cohort of young patients with aortic valve disease. Inputs for early deaths and late complications (death, stroke, bleeding, reoperation) were obtained from a single-centre study of 208 propensity score matched patients. In the primary analysis, the perioperative mortality rate for the Ross procedure was varied by increments of 0.5% to determine its impact on life expectancy and quality-adjusted life years. A 2-way sensitivity analysis was conducted to determine simultaneously the impact of the Ross reoperation rate and Ross reoperative mortality rate on life expectancy. RESULTS: Life expectancy was improved with the Ross procedure when the perioperative mortality rate with the Ross procedure was <2.5% and was equivalent to mAVR when the mortality rate was 2.5% to 5%. Similarly, when the perioperative mortality rate of the Ross procedure was between 4% and 5.5%, the quality-adjusted life years gained were similar between the Ross procedure and mAVR. Life expectancy was improved when the Ross procedure reoperative mortality rate was <7% at an incidence of Ross reoperations of 18% at 20 years. CONCLUSIONS: Improved life expectancy can be expected with the Ross procedure when the operative mortality rate is less than 2.5%.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Tam DY, Wijeysundera HC, Ouzounian M, et al. The Ross procedure versus mechanical aortic valve replacement in young patients: a decision analysis. Eur J Cardiothorac Surg. 2019. PMID: 30535102. doi:10.1093/ejcts/ezy414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。